ODAIA, a Toronto, Canada-based developer of MAPTUAL, an AI-powered commercial insights SaaS platform for pharmaceutical companies, raised an oversubscribed $25 Million Series B financing.
The round was co-led by Threshold Ventures and Monograph Capital, with participation from Wittington Ventures and existing investors Flint Capital, BDC Capital’s Women in Technology Venture Fund, StandUp Ventures, and Graphite Ventures.
With funding, ODAIA to fuel expansion and support the rapid growth of its AI-powered solutions that help pharma companies put life-changing therapies in the hands of patients faster.
“Even in a challenging funding environment, our valued investors clearly recognized the significant problem we’re solving for the pharmaceutical industry,” said Philip Poulidis, CEO and Co-Founder of ODAIA. “With these funds, we’ll continue to evolve our product and build out our team to ensure we’re able to offer our existing and future life science brands the predictive tools needed for today’s market, and tomorrow’s. It’s our pleasure to welcome these investors to the ODAIA team.”
ODAIA is transforming pharmaceutical marketing and commercialization with its lead product, MAPTUAL, a SaaS platform that leverages AI to streamline and automate the prospecting, qualifying, and engagement of healthcare providers (HCP), a process that has largely been manual, labor-intensive, and time-consuming.
With its ability to provide near real-time and predictive perspective on the dynamic changes of the pharmaceutical marketplace, ODAIA’s proprietary platform MAPTUAL empowers leading life science brands to more efficiently get therapeutics, drugs, and vaccines to the markets that need them with a modern, data-driven solution.
Emily Melton, managing partner of Threshold Ventures, and Charles Conn, co-founder and partner of Monograph Ventures, will join ODAIA’s board. Megan Kelly, principal of Threshold Ventures, will also join as a board observer.
Company: ODAIA Intelligence Inc.
Raised: $25.0M
Round: Series B
Funding Month: May 2023
Lead Investors: Threshold Ventures and Monograph Capital
Additional Investors: Wittington Ventures, Flint Capital, BDC Capital’s Women in Technology Venture Fund, StandUp Ventures, and Graphite Ventures
Company Website: https://www.odaia.ai/
Software Category: AI-powered Commercial Insights Software
About the Company: Founded in 2018 out of the University of Toronto, ODAIA is a provider of automated commercial predictive insights trusted by global life sciences organizations. The company leverages proprietary data-driven and AI-powered methods to identify distinct population subsets and their healthcare providers in the most efficient way possible. With ODAIA’s highly scalable and quick-to-deploy software-as-a-service platform, MAPTUAL, pharma sales reps can more efficiently engage with HCPs, sales managers can more effectively coach their teams, and marketers can gain a deep understanding of their market and develop campaigns that deliver strong business results.
Source: https://www.globenewswire.com/news-release/2023/05/01/2658233/0/en/ODAIA-Raises-25-Million-in-Series-B-Funding-to-Advance-Its-AI-Driven-Commercial-Insights-Software-for-Pharma.html